• Home
  • GROUP HOME
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • R&D
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
  • IFU APO-Easy
  • Stability APO-Easy
  • APO-Easy-FLS-OE02-01
  • APO-Easy-FLS-OE02-02
  • APO-Easy-FLS-OE02-03
Firalis
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • R&D
  • Quality
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
contact

Firalis on « Les Echos »

« Les Echos », a prestigious financial journal, published an article on our collaboration with HTG Molecular Diagnostics about the development of a theranostic tool to predict response to anti‑TNFα therapies for Rheumatoid Arthritis (RA). Published on September 12th 2016.

 

Click on the link below to view the related press news:

 

https://www.lesechos.fr/2016/09/firalis-predit-lefficacite-des-therapies-contre-la-polyarthrite-rhumatoide-1112545

« Firalis prédit l'efficacité des thérapies contre la polyarthrite rhumatoïde »

13.03.2020

Follow us on LinkedIn